Mario Malerba

Prof. Mario Malerba

Department of Traslational Medicine, Università del Piemonte Orientale, Head of Respiratory Unit, S.Andrea Hospital, Vercelli, Italy
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2013 in Nature Nanotechnology
Verified
Journal Article
Closed access
AGA. Giugni
A. Giugni
BTB. Torre
B. Torre
ATA. Toma
A. Toma
MFM. Francardi
M. Francardi
Mario MalerbaMario Malerba
Mario Malerba
EFE. Di Fabrizio
E. Di Fabrizio

3 August 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
CFCosimo Franco
Cosimo Franco
NFNicola Facciolongo
Nicola Facciolongo
Roberto TonelliRoberto Tonelli
Roberto Tonelli
RDRoberto Dongilli
Roberto Dongilli
Andrea VianelloAndrea Vianello
Andrea Vianello
stefano navastefano nava
stefano nava
Introduction: The severe acute respiratory syndrome-coronavirus 2 outbreak spread rapidly in Italy and the lack of intensive care unit (ICU) beds soon became evident, forcing the application of noninvasive respiratory support (NRS) outside the ICU, raising concerns over staff contamination. We aimed to analyse the safety of the hospital staff and the feasibility and outcomes of NRS applied to patients outside the ICU.Methods: In this observational study, data from 670 consecutive patients with confirmed coronavirus disease 2019 referred to pulmonology units in nine hospitals between March 1 and May 10, 2020 were analysed. Data collected included medication, mode and usage of NRS (i.e.high-flow nasal cannula (HFNC), continuous positive airway pressure (CPAP), noninvasive ventilation (NIV)), length of stay in hospital, endotracheal intubation (ETI) and deaths.Results: 42 (11.1%) healthcare workers tested positive for infection, but only three of them required hospitalisation. Data are reported for all patients (69.3% male), whose mean±sdage was 68±13 years. The arterial oxygen tension/inspiratory oxygen fraction ratio at baseline was 152±79, and the majority (49.3%) of patients were treated with CPAP. The overall unadjusted 30-day mortality rate was 26.9%, with 16%, 30% and 30% for HFNC, CPAP and NIV, respectively, while the total ETI rate was 27%, with 29%, 25% and 28%, respectively; the relative probability of death was not related to the NRS used after adjustment for confounders. ETI and length of stay were not different among the groups. Mortality rate increased with age and comorbidity class progression.Conclusions: The application of NRS outside the ICU is feasible and associated with favourable outcomes. Nonetheless, it was associated with a risk of staff contamination.

3 September 2014 in Stem Cells
Verified
Journal Article
Open access
PDF file
LTLuca Tirinato
Luca Tirinato
CLCarlo Liberale
Carlo Liberale
Simone Di FrancoSimone Di Franco
Simone Di Franco
Patrizio CandeloroPatrizio Candeloro
Patrizio Candeloro
ABAntonina Benfante
Antonina Benfante
EFEnzo Di Fabrizio
Enzo Di Fabrizio
The cancer stem cell (CSC) model is describing tumors as a hierarchical organized system and CSCs are suggested to be responsible for cancer recurrence after therapy. The identification of specific markers of CSCs is therefore of paramount importance. Here, we show that high levels of lipid droplets (LDs) are a distinctive mark of CSCs in colorectal (CR) cancer. This increased lipid content was clearly revealed by label-free Raman spectroscopy and it directly correlates with well-accepted CR-CSC markers as CD133 and Wnt pathway activity. By xenotransplantation experiments, we have finally demonstrated that CR-CSCs overexpressing LDs retain most tumorigenic potential. A relevant conceptual advance in this work is the demonstration that a cellular organelle, the LD, is a signature of CSCs, in addition to molecular markers. A further functional characterization of LDs could lead soon to design new target therapies against CR-CSCs. Stem Cells 2015;33:35–44

4 August 2008 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
Mario MalerbaMario Malerba
Mario Malerba
BRBeatrice Ragnoli
Beatrice Ragnoli
Background: Belonging to the group of expectorants, ambroxol is an active substance with a long history that influences parameters considered to be the basis for the physiological production and the transport of the bronchial mucus. Therefore, ambroxol's indication is ‘secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport’. Objective: The aim of this review is to evaluate the pharmacological and clinical data on the mucokinetic compound ambroxol. Methods: The existing database that covers > 40 years of pharmacological research and clinical development was analysed. Only studies with adequate study design were evaluated. Conclusion: Ambroxol is shown to exert several activities: i) secretolytic activity (i.e., promotes mucus clearance, facilitates expectoration, and eases productive cough); ii) anti-inflammatory and antioxidant activity; and iii) a local anaesthetic effect through sodium channel blocking at the level of the cell membrane. The reduction on chronic obstructive pulmonary disease exacerbations is consistent and clinically relevant. The anaesthetic effect is a new pharmacological action that could be beneficial in the management of acute respiratory tract infections. The efficacy and safety of ambroxol is well established.

1 March 2012 in Journal of Analytical and Applied Pyrolysis
Verified
Journal Article
Closed access
NMN. Mishra
N. Mishra
GDG. Das
G. Das
AAA. Ansaldo
A. Ansaldo
AGA. Genovese
A. Genovese
Mario MalerbaMario Malerba
Mario Malerba
MSM. Sharon
M. Sharon

1 July 2013 in Nano Letters
Verified
Journal Article
Closed access
FAFrancesco De Angelis
Francesco De Angelis
Mario MalerbaMario Malerba
Mario Malerba
MPMaddalena Patrini
Maddalena Patrini
EMErmanno Miele
Ermanno Miele
GDGobind Das
Gobind Das
EFEnzo Di Fabrizio
Enzo Di Fabrizio